- Home
- LITS vs ATOS Comparison
LITS vs ATOS Comparison
Compare LITS & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LITS | ATOS |
|---|---|---|
| Founded | 2000 | 2009 |
| Country | United States | United States |
| Employees | 4 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.8M | 36.2M |
| IPO Year | N/A | 2010 |
Fundamental Metrics
Financial Performance| Metric | LITS | ATOS |
|---|---|---|
| Price | $1.19 | $4.76 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $31.67 |
| AVG Volume (30 Days) | ★ 338.9K | 116.6K |
| Earning Date | 01-01-0001 | 04-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 16.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,758.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.95 | $0.53 |
| 52 Week High | $3.03 | $7.56 |
Technical Indicators
Market Signals| Indicator | LITS | ATOS |
|---|---|---|
| Relative Strength Index (RSI) | 50.92 | 64.45 |
| Support Level | $1.17 | $0.68 |
| Resistance Level | $1.65 | $7.56 |
| Average True Range (ATR) | 0.07 | 0.33 |
| MACD | 0.02 | -0.09 |
| Stochastic Oscillator | 77.01 | 75.10 |
Price Performance
Historical ComparisonAbout LITS Lite Strategy Inc.
Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients.
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.